NASDAQ:JUNS Jupiter Neurosciences (JUNS) Stock Price, News & Analysis $0.21 -0.07 (-25.00%) Closing price 04:00 PM EasternExtended Trading$0.21 0.00 (-0.95%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Jupiter Neurosciences Stock (NASDAQ:JUNS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Jupiter Neurosciences alerts:Sign Up Key Stats Today's Range$0.20▼$0.2250-Day Range$0.21▼$0.4752-Week Range$0.17▼$3.33Volume3.54 million shsAverage Volume3.90 million shsMarket Capitalization$7.62 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida. Read More Jupiter Neurosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks18th Percentile Overall ScoreJUNS MarketRank™: Jupiter Neurosciences scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingJupiter Neurosciences has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageJupiter Neurosciences has only been the subject of 1 research reports in the past 90 days.Read more about Jupiter Neurosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Jupiter Neurosciences is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Jupiter Neurosciences is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Jupiter Neurosciences' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.95% of the float of Jupiter Neurosciences has been sold short.Short Interest Ratio / Days to CoverJupiter Neurosciences has a short interest ratio ("days to cover") of 0.07, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Jupiter Neurosciences has recently decreased by 72.89%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldJupiter Neurosciences does not currently pay a dividend.Dividend GrowthJupiter Neurosciences does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.79 News SentimentJupiter Neurosciences has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Jupiter Neurosciences this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for JUNS on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat Follows1 people have added Jupiter Neurosciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Jupiter Neurosciences insiders have not sold or bought any company stock.Percentage Held by Insiders38.60% of the stock of Jupiter Neurosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsJupiter Neurosciences has minimal institutional ownership at this time.Read more about Jupiter Neurosciences' insider trading history. Receive JUNS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jupiter Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JUNS Stock News HeadlinesJupiter Neurosciences, Inc. (NASDAQ:JUNS) Short Interest UpdateJune 27 at 4:07 AM | americanbankingnews.comJupiter Neurosciences Inc.May 30, 2026 | barrons.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.June 29 at 1:00 AM | Banyan Hill Publishing (Ad)D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. in Connection with its ~$2 Million Registered Direct OfferingMay 27, 2026 | finanznachrichten.deJupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s DiseaseMay 27, 2026 | markets.businessinsider.comJupiter Neurosciences, Inc. Initiates Patient Enrollment for Phase 2a RESET Trial of JOTROL™ in Parkinson’s DiseaseMay 27, 2026 | quiverquant.comQJupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's DiseaseMay 27, 2026 | globenewswire.comJupiter Neurosciences, Inc. Secures $2 Million in Direct Offering to Support Parkinson’s Program and Strengthen Balance SheetMay 21, 2026 | quiverquant.comQSee More Headlines JUNS Stock Analysis - Frequently Asked Questions How have JUNS shares performed this year? Jupiter Neurosciences' stock was trading at $1.02 at the beginning of the year. Since then, JUNS stock has decreased by 79.4% and is now trading at $0.21. How were Jupiter Neurosciences' earnings last quarter? Jupiter Neurosciences, Inc. (NASDAQ:JUNS) released its quarterly earnings data on Thursday, May, 14th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by $0.01. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.23 million. When did Jupiter Neurosciences IPO? Jupiter Neurosciences (JUNS) raised $11 million in an initial public offering on Tuesday, December 3rd 2024. The company issued 2,800,000 shares at a price of $4.00 per share. Dominari Securities and Revere Securities served as the underwriters for the IPO. Who are Jupiter Neurosciences' major shareholders? Top institutional shareholders of Jupiter Neurosciences include Vestor Capital LLC (2.68%). View institutional ownership trends. How do I buy shares of Jupiter Neurosciences? Shares of JUNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/14/2026Today6/29/2026Next Earnings (Estimated)9/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 JUNS's financial health is in the Yellow zone, according to TradeSmith. JUNS has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryN/A Current SymbolNASDAQ:JUNS CIK1679628 Webwww.jupiterorphan.com Phone561 406 6154FaxN/AEmployees5Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.65 million Net MarginsN/A Pretax Margin-22,385.37% Return on Equity-1,314.62% Return on Assets-228.63% Debt Debt-to-Equity RatioN/A Current Ratio0.51 Quick Ratio0.48 Sales & Book Value Annual Sales$20 thousand Price / Sales380.94 Cash FlowN/A Price / Cash FlowN/A Book Value($0.05) per share Price / Book-4.20Miscellaneous Outstanding Shares36,280,000Free Float22,277,000Market Cap$7.62 million OptionableNot Optionable Beta1.72 10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:JUNS) was last updated on 6/29/2026 by MarketBeat.com Staff. From Our PartnersTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredSpaceX is offering you shares. Don't take them.SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $...Behind the Markets | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jupiter Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jupiter Neurosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
